Serum vascular endothelial growth factor levels as a marker of skin thickening, digital ischemia, and interstitial lung disease in systemic sclerosis

Chinnadurai, Sivakumar; Ramamoorthy, R.; Mahendran, Bhuvanesh; Chilukuri, B.; Balameena, S; Rajeswari, S.

doi:10.4103/injr.injr_132_17

Cited by 3 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, serum VEGF levels showed positive correlation with 6MWD, and a significant positive correlation with FVC %, but showed inverse correlation with percent desaturation during 6MWT, MMRC score, presence of pulmonary hypertension, tricuspid annular plane systolic excursion, and right-sided cardiac dilatation, and this was statistically insignificant. Saranya et al [15] found that serum VEGF levels were inversely correlated with FVC and that there was a significant positive correlation with the MMRC dyspnea score.…”

Section: Discussionmentioning

confidence: 98%

“…Previous studies by Hashimoto et al [13] and Kikuchi et al [14] found that serum VEGF levels were significantly higher in patients with rheumatic diseases compared with healthy controls, and VEGF levels were correlated with the presence of ILD. Saranya et al [15] reported that median serum VEGF in systemic sclerosis patients was significantly higher than in controls; also, De Santis et al [16] found that serum VEGF was higher in systemic sclerosis patients versus healthy controls with lower VEGF levels in the serum of patients with evidence of ILD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vascular endothelial growth factor in hypersensitivity pneumonitis and connective tissue disease-associated interstitial lung disease

El-Hinnawy,

El-Ghobashy,

Halim

et al. 2024

Egypt J Bronchol

View full text Add to dashboard Cite

Background A growing evidence on the role of vascular endothelial growth factor (VEGF) in the pathogenesis of interstitial lung diseases accumulated over the past decade; with the development of nintedanib for the treatment of fibrotic interstitial lung diseases, our aim was to quantify serum levels of VEGF in patients’ hypersensitivity pneumonitis (HP) and connective tissue disease-associated interstitial lung diseases (CTD-ILD) with an assessment of its relationship with functional status parameters and echocardiographic findings. Methods Spirometry, 6-min walking test, echocardiography, and serum VEGF levels were assessed in HP and CTD-ILD patients. Results The study included 31 HP patients, 30 CTD-ILD patients, and 29 control subjects. VEGF level was significantly higher in HP patients than in patients with CTD-ILD and control subjects. VEGF level showed positive correlation with 6-min walk distance and forced vital capacity percent predicted and inverse correlation with percent desaturation in 6-min walk test, dyspnea score, and echocardiographic findings in both groups. Conclusion Serum VEGF is higher in HP patients than in patients with CTD-ILD and control.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Vascular endothelial growth factor in hypersensitivity pneumonitis and connective tissue disease-associated interstitial lung disease

El-Hinnawy,

El-Ghobashy,

Halim

et al. 2024

Egypt J Bronchol

View full text Add to dashboard Cite

show abstract

Association of Circulating Vascular Endothelial Growth Factor Levels With Autoimmune Diseases: A Systematic Review and Meta-Analysis

Zhan

Liu

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

BackgroundAutoimmune diseases (ADs) are characterized by immune-mediated tissue damage, in which angiogenesis is a prominent pathogenic mechanism. Vascular endothelial growth factor (VEGF), an angiogenesis modulator, is significantly elevated in several ADs including rheumatoid arthritis (RA), systemic sclerosis (SSc), and systemic lupus erythematosus (SLE). We determined whether circulating VEGF levels were associated with ADs based on pooled evidence.MethodsThe analyses included 165 studies from the PubMed, EMBASE, Cochrane Library, and Web of Science databases and fulfilled the study criteria. Comparisons of circulating VEGF levels between patients with ADs and healthy controls were performed by determining pooled standard mean differences (SMDs) with 95% confidence intervals (CIs) in a random-effect model using STATA 16.0. Subgroup, sensitivity, and meta-regression analyses were performed to determine heterogeneity and to test robustness.ResultsCompared with healthy subjects, circulating VEGF levels were significantly higher in patients with SLE (SMD 0.84, 95% CI 0.25–1.44, P = 0.0056), RA (SMD 1.48, 95% CI 0.82–2.15, P <0.0001), SSc (SMD 0.56, 95% CI 0.36–0.75, P <0.0001), Behcet’s disease (SMD 1.65, 95% CI 0.88–2.41, P <0.0001), Kawasaki disease (SMD 2.41, 95% CI 0.10–4.72, P = 0.0406), ankylosing spondylitis (SMD 0.78, 95% CI 0.23–1.33, P = 0.0052), inflammatory bowel disease (SMD 0.57, 95% CI 0.43–0.71, P <0.0001), psoriasis (SMD 0.98, 95% CI 0.62–1.34, P <0.0001), and Graves’ disease (SMD 0.69, 95% CI 0.20–1.19, P = 0.0056). Circulating VEGF levels correlated with disease activity and hematological parameters in ADs.ConclusionCirculating VEGF levels were associated with ADs and could predict disease manifestations, severity and activity in patients with ADs.Systematic Review RegistrationPROSPERO, identifier CRD42021227843.

show abstract

Vascular endothelial growth factor as a potential biomarker in systemic sclerosis: a systematic review and meta-analysis

Zinellu,

Mangoni

2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionSystemic sclerosis (SSc), a chronic autoimmune condition, is characterized by microvascular dysfunction, ineffective angiogenesis, and fibrosis. The identification of robust biomarkers reflecting these processes may assist in clinical management and lead to the discovery of new therapies. We sought to address this issue by conducting a systematic review and meta-analysis of studies investigating one such biomarker, vascular endothelial growth factor (VEGF), in SSc patients and healthy controls and in SSc patients with localized or diffuse disease, different video capillaroscopy patterns (early, active, or late), and presence or absence of complications.MethodsWe searched PubMed, Scopus, and Web of Science from inception to 15 May 2024. We assessed the risk of bias and the certainty of evidence using the JBI checklist for analytical studies and GRADE, respectively.ResultsIn 42 eligible studies, compared to controls, patients with SSc had significantly higher plasma or serum VEGF concentrations (standard mean difference, SMD=0.93, 95% CI 0.71 to 1.15, p<0.001; moderate certainty). In further analyses, VEGF concentrations were significantly higher in SSc patients with diffused disease than those with localized disease (SMD=0.30, 95% CI 0.01 to 0.59, p=0.046; very low certainty), in patients with late vs. active video capillaroscopy pattern (SMD=0.35, 95% CI 0.09 to 0.61, p=0.008; very low certainty), and in patients with pulmonary hypertension than those without (SMD=0.93, 95% CI 0.34 to 1.53, p=0.002; very low certainty). By contrast, no significant differences were observed between SSc patients with and without digital ulcers, interstitial lung disease, and telangiectasias, whereas limited evidence was available for alveolitis. Meta-regression and subgroup analysis of studies investigating VEGF in SSc patients and controls showed no significant associations between the effects size and various patient and study characteristics, including SSc duration and use of corticosteroids, immunosuppressors and vasodilators. By contrast, significant associations were observed with the geographical location where the study was conducted.DiscussionThe results of this systematic review and meta-analysis suggest that VEGF can be useful in the assessment and management of SSc and in the identification of novel therapeutic strategies in this patient group.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero, identifier CRD42024552925.

show abstract

Serum vascular endothelial growth factor levels as a marker of skin thickening, digital ischemia, and interstitial lung disease in systemic sclerosis

Cited by 3 publications

References 1 publication

Vascular endothelial growth factor in hypersensitivity pneumonitis and connective tissue disease-associated interstitial lung disease

Vascular endothelial growth factor in hypersensitivity pneumonitis and connective tissue disease-associated interstitial lung disease

Association of Circulating Vascular Endothelial Growth Factor Levels With Autoimmune Diseases: A Systematic Review and Meta-Analysis

Vascular endothelial growth factor as a potential biomarker in systemic sclerosis: a systematic review and meta-analysis

Contact Info

Product

Resources

About